Looking for treatment? Call or text (888) 835-9995 to start care today — or return to the homepage.
Standard panels
Most standard drug tests do not detect buprenorphine.
The most common workplace drug screen — the SAMHSA-5, also called a 5-panel test — tests for amphetamines, cocaine, marijuana, opiates, and phencyclidine (PCP). Buprenorphine is not included.
A 10-panel test adds barbiturates, benzodiazepines, methaqualone, methadone, and propoxyphene to the standard five. Buprenorphine is not included in most standard 10-panel tests unless it is specifically added to the panel.
Extended panels exist that specifically test for buprenorphine. These are increasingly used in clinical settings — particularly in substance use treatment programs — and may be ordered by some employers or courts. When in doubt, ask what specific substances the test screens for.
Detection windows
How long buprenorphine is detectable depends on the specimen.
Detection windows are approximate and vary based on dose, frequency of use, metabolism, body composition, and kidney function. The figures below represent typical ranges based on published pharmacokinetic data.
Urine
The most common specimen type. Buprenorphine and its metabolite norbuprenorphine are typically detectable in urine for approximately 3–7 days after the last dose at standard doses. At higher doses or after extended use, detection may extend to approximately 10–14 days.
Saliva
Oral fluid testing detects buprenorphine for approximately 1–3 days after the last dose. Saliva testing is less common for buprenorphine, though it may be used in some point-of-care or forensic settings.
Blood
Blood testing provides a shorter detection window — typically about 24–72 hours for buprenorphine. Blood tests are less common outside of clinical or forensic contexts.
Hair
Hair follicle testing can detect buprenorphine for up to 90 days, consistent with the standard hair testing window. Hair tests are uncommon for buprenorphine but are used in some clinical and legal settings.
In clinical treatment
Drug testing in buprenorphine treatment.
Drug testing in medication treatment programs serves a different purpose than employment screening. Clinical testing is used to monitor treatment progress, assess medication adherence, and identify co-occurring substance use that may affect safety — not to create grounds for discharge.
A positive result for buprenorphine on a clinical test may support adherence, though interpretation depends on the type of test and the clinical context. A negative result when a patient is prescribed buprenorphine may prompt a clinical conversation about adherence or test interpretation, not automatic discharge.
At MyStreetHealth, drug testing results are treated as clinical information — used to inform care decisions, not to punish patients.
Sources
Where this information comes from.
SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing
Defines standard panels and cutoff levels for federally mandated workplace drug testing.
Donroe JH et al. — Buprenorphine and Norbuprenorphine Urine Levels (CCJM 2022)
How to interpret quantitative buprenorphine and norbuprenorphine urine levels in clinical practice, including detection windows and clinical significance.
Mayo Clinic Laboratories — Buprenorphine and Norbuprenorphine, Urine
Detection methodology, cutoff levels, and clinical notes on buprenorphine urine testing from Mayo Clinic Laboratories.
ASAM National Practice Guideline (2020)
Guidance on drug testing in medication treatment programs — purpose, frequency, and interpretation.
Overview of buprenorphine treatment, including monitoring and urine drug testing considerations.